In which scenario is dual antiplatelet therapy commonly considered?

In which scenario is dual antiplatelet therapy commonly considered?

• A. In selected minor ischemic strokes and certain TIAs to reduce early recurrence (short-term), under clinician guidance
• B. In all strokes regardless of severity
• C. Never used in stroke management
• D. Only for hemorrhagic stroke

Answer: (A)

Dual antiplatelet therapy is considered after selected minor ischemic strokes and certain TIAs to reduce the risk of early recurrent ischemia. The early period after these events carries the highest chance of another stroke, and adding a second antiplatelet agent provides more robust platelet inhibition than a single agent alone. However, this approach increases bleeding risk, so it’s used only under careful clinician guidance and for a short duration (commonly around 21 days) before returning to single antiplatelet therapy. It is not applied to all strokes, and it is not used in hemorrhagic stroke, where bleeding risk would worsen. This brief, targeted use after minor events is why the described scenario is the best fit.

Dual antiplatelet therapy is considered after selected minor ischemic strokes and certain TIAs to reduce the risk of early recurrent ischemia. The early period after these events carries the highest chance of another stroke, and adding a second antiplatelet agent provides more robust platelet inhibition than a single agent alone. However, this approach increases bleeding risk, so it’s used only under careful clinician guidance and for a short duration (commonly around 21 days) before returning to single antiplatelet therapy. It is not applied to all strokes, and it is not used in hemorrhagic stroke, where bleeding risk would worsen. This brief, targeted use after minor events is why the described scenario is the best fit.